FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Glenmark Pharmaceuticals Alyacen 7/7/7 Recall

Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0

Glenmark Pharmaceuticals Inc., USA · Elmwood Park, NJ

Risk level
Class II
Reported by FDA
Jun 24, 2026
Recall ID
D-0588-2026
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Alyacen 7/7/7 starting May 27, 2026. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0588-2026 on Jun 24, 2026. Reason: Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities. Status: Ongoing.

Why it was recalled

Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Product description

Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0.5mg/0.035mg, 0.75mg/0.035mg, 1 mg/0.0.35mg, 3 Blister Cards each containing 28 tablets, 28 day regimen, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Colvale-Bardez, Goa 403 513, India, Manufactured for: Glenmark Pharmaceuticals Inc., Mahwah, NJ 07430, NDC 68462-556-29

Lot numbers, UPCs & expiration codes

Lot #: 20240411, Exp: 6/30/2026; 20250252, Exp: 3/31/2027

Where it was sold

USA Nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0588-2026
Classification
Class II
Status
Ongoing
Recall initiated
May 27, 2026
FDA report date
Jun 24, 2026
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0588-2026, exactly as published.

Show all FDA fields
City
Elmwood Park
State
NJ
Status
Ongoing
Country
United States
Event ID
99101
Address
619 River Dr
Code information
Lot #: 20240411, Exp: 6/30/2026; 20250252, Exp: 3/31/2027
Postal code
07407-1317
Report date
Jun 24, 2026
Product type
Drugs
Recall number
D-0588-2026
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Reason for recall
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0.5mg/0.035mg, 0.75mg/0.035mg, 1 mg/0.0.35mg, 3 Blister Cards each containing 28 tablets, 28 day regimen, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Colvale-Bardez, Goa 403 513, India, Manufactured for: Glenmark Pharmaceuticals Inc., Mahwah, NJ 07430, NDC 68462-556-29
Distribution pattern
USA Nationwide.
Recall initiation date
May 27, 2026
Initial firm notification
Letter
Center classification date
Jun 12, 2026

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0588-2026, published Jun 24, 2026. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls